Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs

Vaccine

Volumn 36, Issue 26, 2018, Pages 3820-3829

  Dillner, Joakim ^a   Nygård, Mari ^b   Munk, Christian ^c   Hortlund, Maria ^a   Hansen, Bo T ^b   Lagheden, Camilla ^a   Liaw, Kai Li ^d   Kjaer, Susanne K ^c,e  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Human papillomavirus; Liquid based cytology; Quadrivalent HPV vaccine; Scandinavia; Type specific HPV

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DENMARK; FEMALE; FOLLOW UP; GENOTYPE; HEALTH IMPACT ASSESSMENT; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION CONTROL; MIDDLE AGED; NORWAY; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGRAM EVALUATION; SCANDINAVIA; SWEDEN; TOTAL QUALITY MANAGEMENT; VACCINATION; YOUNG ADULT; AGED; CHILD; CLASSIFICATION; EARLY CANCER DIAGNOSIS; GENETICS; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PREVENTIVE HEALTH SERVICE; UTERINE CERVIX TUMOR; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DENMARK; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNIZATION PROGRAMS; MIDDLE AGED; NORWAY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SWEDEN; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 85046881596     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2018.05.019     Document Type: Article

References (26)

1. Bosch, F.X., Burchell, A.N., Schiffman, M., Giuliano, A.R., de Sanjose, S., Bruni, L., et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26:Suppl. 10 (2008), K1–K16.
2. Alemany, L., de Sanjose, S., Tous, S., Quint, W., Vallejos, C., Shin, H.R., et al. Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007. Int J Cancer 135:1 (2014), 88–95.
3. A Review of Human Carcinogens. B. Biological Agents. IARC monographs on the evaluation of carcinogenic risks to humans. 2012;100B:255–313.
4. Human papillomavirus vaccines: WHO position paper, May 2017. 12 MAY 2017, 92nd YEAR; No 19, 2017, 92, 241-68. < http://www.who.int/wer/2017/wer9219/en/> [accessed 03.04.18].
5. Baussano, I., Garnett, G., Segnan, N., Ronco, G., Vineis, P., Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. Vaccine 29 (2011), 1270–1277.
6. Garnett, G.P., Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 191:Suppl. 1 (2005), S97–S106.
7. Tota, J.E., Ramanakumar, A.V., Jiang, M., Dillner, J., Walter, S.D., Kaufman, J.S., et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol 178 (2013), 625–634.
8. IARC. Cervix cancer screening. IARC handbooks of cancer prevention. 2005;10:1–313.
9. Laara, E., Day, N.E., Hakama, M., Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1 (1987), 1247–1249.
10. Elfström, K.M., Sparen, P., Olausson, P., Almstedt, P., Strander, B., Registry-based assessment of the status of cervical screening in Sweden. J Med Screen 23 (2016), 217–226.
11. Lee LY, Garland SM. Human papillomavirus vaccination: the population impact. F1000Res 2017;6:866.
12. Folkhälsomyndigheten. The public health agency of sweden. In: Statistics for HPV vaccinations – proportions of vaccinated girls through 2016-12-31. < https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistikdatabaser-och-visualisering/vaccinationsstatistik/statistik-for-hpv-vaccinationer/>. [accessed 22.02.18].
13. Soderlund-Strand, A., Eklund, C., Kemetli, L., Grillner, L., Tornberg, S., Dillner, J., et al. Genotyping of human papillomavirus in triaging of low-grade cervical cytology. Am J Obstet Gynecol 205:145 (2011), e1–e6.
14. Wheeler, C.M., Kjaer, S.K., Sigurdsson, K., Iversen, O.E., Hernandez-Avila, M., Perez, G., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis 199:7 (2009), 936–944.
15. Franco, E.L., Duarte-Franco, E., Ferenczy, A., Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 164:7 (2001), 1017–1025.
16. Janicek, M.F., Averette, H.E., Cervical cancer: prevention, diagnosis, and therapeutics. CA Cancer J Clin 51:2 (2001), 92–114.
17. Chow, E.P., Danielewski, J.A., Fehler, G., Tabrizi, S.N., Law, M.G., Bradshaw, C.S., et al. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis 15 (2015), 1314–1323.
18. Baldur-Felskov, B., Dehlendorff, C., Junge, J., Munk, C., Kjaer, S.K., Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 25:7 (2014), 915–922.
19. Leval, A., Herweijer, E., Ploner, A., Eloranta, S., Fridman Simard, J., Dillner, J., et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst 105 (2013), 469–474.
20. Soderlund-Strand, A., Uhnoo, I., Dillner, J., Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study. Cancer Epidemiol Biomarkers Prev 23 (2014), 2757–2764.
21. Drolet, M., Benard, E., Boily, M.C., Ali, H., Baandrup, L., Bauer, H., et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15 (2015), 565–580.
22. Tabrizi, S.N., Brotherton, J.M., Kaldor, J.M., et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 14:10 (2014), 958–966.
23. Garland, S.M., Kjaer, S.K., Munoz, N., et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 63:4 (2016), 519–527.
24. Joura, E.A., Giuliano, A.R., Iversen, O.E., Bouchard, C., Mao, C., Mehlsen, J., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372 (2015), 711–723.
25. Baussano, I., Lazzarato, F., Ronco, G., Lehtinen, M., Dillner, J., Franceschi, S., Different challenges in eliminating HPV16 compared to other types: a modeling study. J Infect Dis 216:3 (2017), 336–344.
26. Center for Cervical Cancer Prevention. National Quality for Cervical Cancer Prevention_Analys. < http://www.nkcx.se/> [accessed 03.04.18].